动物造模,慢性睡眠干扰 z-bio 2021-07-19 405

　　Objective: To study the antidepressant effect of ginsenoside hydrolysate DS-1226 on mice with chronic sleep disorders, and to provide a scientific basis for the development of antidepressants.

　　Methods: Blank control group, model group, positive control group (paroxetine hydrochloride, 10mg/kg), DS-1226 low-dose group (20mg/kg), middle-dose group (40mg/kg) 72 male ICR mice) were divided into . ), high-dose group (80 mg/kg). Except for the blank group, the mice in the other groups were first adapted to the roller for 3 days, and then continuously disturbed for 14 days. The antidepressant effects of DS-1226 were evaluated using experimental methods such as weight monitoring, autonomous activity experiment, tail suspension experiment and forced swimming experiment.

　　Results: After 14 days of continuous sleep disturbance, the model group had a significant weight loss compared with the blank control group, and the time of tail suspension and forced swimming immobility was significantly increased. .. Compared with the model group, the DS-1226 medium-dose group significantly reversed the weight loss caused by sleep disorders, while the other drug group significantly reversed the weight loss caused by sleep disorders. The fixed tail suspension. Significantly reduced, forced swimming immobility time tends to decrease; DS-1226 medium-dose tail suspension time tends to be significantly reduced, forced swimming immobility time tends to significantly reduce; DS-1226 in the high-dose group has tail suspension and The time of forced swimming immobility is greatly reduced.

　　Conclusion: DS-1226 has the effect of improving depression-like behavior in mice with chronic sleep disorders.